Back to Search Start Over

Toward measuring effective treatment coverage: critical bottlenecks in quality- and user-adjusted coverage for major depressive disorder.

Authors :
Vigo D
Haro JM
Hwang I
Aguilar-Gaxiola S
Alonso J
Borges G
Bruffaerts R
Caldas-de-Almeida JM
de Girolamo G
Florescu S
Gureje O
Karam E
Karam G
Kovess-Masfety V
Lee S
Navarro-Mateu F
Ojagbemi A
Posada-Villa J
Sampson NA
Scott K
Stagnaro JC
Ten Have M
Viana MC
Wu CS
Chatterji S
Cuijpers P
Thornicroft G
Kessler RC
Source :
Psychological medicine [Psychol Med] 2020 Oct 20, pp. 1-11. Date of Electronic Publication: 2020 Oct 20.
Publication Year :
2020
Publisher :
Ahead of Print

Abstract

Background: Major depressive disorder (MDD) is a leading cause of morbidity and mortality. Shortfalls in treatment quantity and quality are well-established, but the specific gaps in pharmacotherapy and psychotherapy are poorly understood. This paper analyzes the gap in treatment coverage for MDD and identifies critical bottlenecks.<br />Methods: Seventeen surveys were conducted across 15 countries by the World Health Organization-World Mental Health Surveys Initiative. Of 35 012 respondents, 3341 met DSM-IV criteria for 12-month MDD. The following components of effective treatment coverage were analyzed: (a) any mental health service utilization; (b) adequate pharmacotherapy; (c) adequate psychotherapy; and (d) adequate severity-specific combination of both.<br />Results: MDD prevalence was 4.8% (s.e., 0.2). A total of 41.8% (s.e., 1.1) received any mental health services, 23.2% (s.e., 1.5) of which was deemed effective. This 90% gap in effective treatment is due to lack of utilization (58%) and inadequate quality or adherence (32%). Critical bottlenecks are underutilization of psychotherapy (26 percentage-points reduction in coverage), underutilization of psychopharmacology (13-point reduction), inadequate physician monitoring (13-point reduction), and inadequate drug-type (10-point reduction). High-income countries double low-income countries in any mental health service utilization, adequate pharmacotherapy, adequate psychotherapy, and adequate combination of both. Severe cases are more likely than mild-moderate cases to receive either adequate pharmacotherapy or psychotherapy, but less likely to receive an adequate combination.<br />Conclusions: Decision-makers need to increase the utilization and quality of pharmacotherapy and psychotherapy. Innovations such as telehealth for training and supervision plus non-specialist or community resources to deliver pharmacotherapy and psychotherapy could address these bottlenecks.

Details

Language :
English
ISSN :
1469-8978
Database :
MEDLINE
Journal :
Psychological medicine
Publication Type :
Academic Journal
Accession number :
33077023
Full Text :
https://doi.org/10.1017/S0033291720003797